Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.69 CHF | -4.43% | +0.15% | +35.15% |
Apr. 17 | Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member | CI |
Mar. 19 | Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 22
Sales per Business
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Drugs
100.0
%
| 6 | 100.0 % | 9 | 100.0 % | +43.85% |
Sales per region
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Italy & United States
100.0
%
| 6 | 100.0 % | 9 | 100.0 % | +43.85% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-12-31 |
Filippo Moriggia
COO | Chief Operating Officer | - | 16-10-31 |
Ravi Anand
CTO | Chief Tech/Sci/R&D Officer | 67 | 04-12-31 |
Laura Faravelli
PRN | Corporate Officer/Principal | - | 18-12-31 |
Dennis Dionne
PRN | Corporate Officer/Principal | - | 14-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 07-12-31 | |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Ulrich Köstlin
CHM | Chairman | 71 | 12-12-31 |
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 18,631,834 | 17,158,913 ( 92.09 %) | 0 | 92.09 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+39.60% | 143M | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.94% | 29.36B | |
+53.87% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-17.60% | 11.62B | |
-13.96% | 11.31B | |
+2.25% | 8.31B |
- Stock Market
- Equities
- NWRN Stock
- Company Newron Pharmaceuticals S.p.A.